Zymeworks Inc is a Vancouver-based clinical-stage biopharmaceutical company that specializes in discovering, developing, and commercializing biotherapeutics for cancer treatment. The company's main candidates for treatment include zanidatamab and ZW49, which are both undergoing clinical trials for the treatment of different types of cancer. Zymeworks has various partnerships with several companies in the pharmaceutical industry, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others.